Breast cancers that are (ER+/PR+) are likely to respond to hormone therapy such as tamoxifen and anastrozole [23], while the prophylatic use of tamoxifen, raloxifene, or anastrozole is recommended for postmenopausal women at high risk of developing breast cancer [30,31]. This evidence concerns the gene ESR1 and breast carcinoma.